Skip to main content
SURAKSHA DIAGNOSTIC LIMITED logo

SURAKSHA DIAGNOSTIC LIMITED — Investor Relations & Filings

Ticker · SURAKSHA ISIN · INE877V01027 LEI · 335800SJSOH7ZQHTPO56 BSE.NS Human health and social work activities
Open in API
Filings indexed 144 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country IN India
Listing BSE.NS SURAKSHA

About SURAKSHA DIAGNOSTIC LIMITED

https://www.surakshanet.com

Suraksha Diagnostic Limited is a prominent diagnostic healthcare service provider primarily operating in Eastern India. The company offers a comprehensive range of pathology and radiology services, including clinical laboratory tests, molecular diagnostics, and advanced imaging such as MRI, CT scans, ultrasound, and X-rays. It operates a network of diagnostic centers and polyclinics, providing integrated healthcare solutions that encompass specialized consultations and preventive health check-ups. The organization is recognized for its commitment to quality, maintaining international standards through NABL and CAP accreditations. By leveraging advanced medical technology and a robust logistics framework for home collection, the company serves a diverse patient base, focusing on accurate clinical outcomes and accessible diagnostic care.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Regulatory Filings Classification · 80% confidence The document is an exchange filing under SEBI LODR Regulation 30, titled “Outcome of the Board meeting,” submitted to BSE and NSE. It discloses the board’s approval of audited financial results, dividend recommendation, AGM notice, auditor appointments, etc., and includes annexures with the audit report and financial statements. It is not the company’s full annual report (10-K), not a pure earnings press release (ER), and not a formal interim report (IR) by U.S./SEC standards, nor is it merely announcing a future report publication. It is a general regulatory announcement/compliance filing under Indian securities regulations, best fitting the “Regulatory Filings” category (RNS).
2026-05-21 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 94% confidence The document is a SEBI Listing Regulations disclosure of board meeting outcomes, notably the approval and publication of audited standalone and consolidated financial results for the quarter and financial year ended 31 March 2026, accompanied by full financial statements (profit & loss, assets & liabilities, cash flow) and the independent auditor’s report. It is not an Annual Report (10-K), which would include narrative and MD&A, nor merely an Earnings Release (ER), which would provide only headline metrics. Instead, it contains comprehensive interim/quarterly financial statements and qualifies as an Interim/Quarterly Report under the classification rules. FY 2026
2026-05-21 English
Dividend
Regulatory Filings Classification · 93% confidence The document is a SEBI Listing Regulations (Regulation 30 and 33) compliance filing, titled “Outcome of the Board meeting,” addressed to the stock exchanges. It includes the audited financial results for the quarter and year ended March 31, 2026, alongside the Statutory Auditor’s report, dividend recommendation, AGM notice, record date, and auditor appointments. It is not a full Annual Report (10-K) but rather a regulatory announcement of board approvals and attached financial statements under listing obligations. This falls under general regulatory announcements and compliance filings rather than a standalone financial report category, so it should be classified as Regulatory Filings (RNS).
2026-05-21 English
Outcome of Board meeting held today, i.e 21 May 2026
Interim / Quarterly Report Classification · 85% confidence The document is a SEBI LODR stock‐exchange filing announcing the Outcome of the Board Meeting, including the audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, the Independent Auditor’s Report, statement of assets & liabilities, and cash flow statement. It is not a full Annual Report (10‐K) but contains substantive financial statements and audit opinion. It is not merely an announcement of availability (RPA) nor a certification letter (RNS). As it contains the actual periodic financial results, it fits the Interim/Quarterly Report category. FY 2026
2026-05-21 English
Outcome of Board Meeting
Regulatory Filings Classification · 85% confidence The document is a formal intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, notifying stock exchanges of the Board meeting outcome: approval of audited standalone and consolidated results for Q4 and FY ended March 31, 2026, dividend recommendation, AGM notice, record date, and auditor appointments. It is not the full annual report itself but a regulatory announcement of corporate actions and attached audited results. This falls under general regulatory filings (RNS).
2026-05-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 76% confidence The document is a formal disclosure under SEBI Listing Regulations to the stock exchanges informing of the date, time and dial-in details for the company’s upcoming earnings conference call. It does not contain financial results or analysis (so it is not an ER or IR), nor the investor presentation itself (so it is not IP), nor a transcript (CT), but is a regulatory announcement. It therefore falls under Regulatory Filings (RNS).
2026-05-15 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.